Complete Story


FDA Clears AstraZeneca's COVID Antibody Treatment for Immunocompromised

Evusheld can be used against pre-exposure prophylaxis

The Food and Drug Administration (FDA) authorized the first injectable monoclonal antibody cocktail for long-term prevention of Covid-19 among people with weakened immune systems before they have been exposed to the coronavirus.

The FDA issued an emergency use authorization Wednesday for AstraZeneca’s antibody cocktail, Evusheld, for what is known as pre-exposure prophylaxis, or PrEP, against Covid-19. 

To date, such laboratory-produced antibodies have been authorized only as early treatment of COVID-19 or as preventive therapy for high-risk people immediately after close contact with someone who has tested positive.

Please select this link to read the complete article from NBC News.

Printer-Friendly Version